Medical devices, healthcare technology and the business of care
510(k) clearance · K263232

eplex RP3 Control M530; eplex RP3 Negative

Maine Molecular Quality Controls, Inc. · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONK263232

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 10/30/2026 for eplex RP3 Control M530 and eplex RP3 Negative, submitted by Maine Molecular Quality Controls, Inc. of Saco, Maine, under 510(k) number K263232. The device falls under the classification name Assayed External Control Material For Microbiology Nucleic Acid Amplification (NAT) Assays, regulation number 866.3920, with product code PMN and Microbiology as the regulation medical specialty and review panel. The application was received 09/16/2026.

SESE in the 510(k) pathway denotes clearance to market, not premarket approval. The record identifies the submission as a Traditional 510(k) that was not reviewed by a third party, was not a combination product, and had no authorized Predetermined Change Control Plan. The page does not state which components or changes were assessed, the predicate device, or any performance data, so the technical basis for the clearance remains unknown from this record.

The listed applicant contact and correspondent contact are both Joan Gordon at the same Saco address. No summary statement content is captured in the available text, and the page was last updated 11/09/2026.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 30, 2026
FDA decision documents: 510(k) Premarket Notification

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K263232
Regulatory pathway
510(k) premarket notification
Product code
PMN
Decision code
SESE
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays.

Product code
PMN
FDA device class
2

FDA decision timeline

  1. K263232 received

    Application receipt date recorded by FDA.

  2. K263232 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code PMN

Product / regulatory recordCompanyPathwayDecision dateSource
BioFire Defense, LLC510(k) clearanceNov 4, 2026FDA
Maine Molecular Quality Controls, Inc.510(k) clearanceOct 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Maine Molecular Quality Controls, Inc.

Headquarters
Not reported
Brand website
mmqci.com
FDA applicant address
Saco, ME

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records